(Q26995169)

Elizabeth McNeely

2

1 reference

Tess Lin

3

1 reference

Kirkwood Adams

4

1 reference

J. Patterson

5

1 reference

language of work or name

1 reference

12 November 2014

1 reference

Journal of Clinical Medicine

published in

1 reference

volume

3

1 reference

issue

4

1 reference

page(s)

1276-90

1 reference

Creative Commons Attribution 4.0 International

copyright license

start time

12 November 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470182

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470182

Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470182

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470182

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470182

Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470182

Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470182

Vasopressin: a new target for the treatment of heart failure

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470182

Hyponatremia in patients with heart failure

28 September 2017

1 reference

https://api.crossref.org/works/10.3390%2FJCM3041276

Hyponatremia and heart failure--pathophysiology and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM3041276

Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM3041276

Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM3041276

Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM3041276

Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJCM3041276

Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide

21 January 2018

1 reference

12 December 2020

In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

1 reference

12 December 2020

Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers

1 reference

12 December 2020

Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects

1 reference

12 December 2020

Relative bioavailability of tolvaptan administered via nasogastric tube and tolvaptan tablets swallowed intact

1 reference

12 December 2020

Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan and Warfarin in Healthy Subjects.

1 reference

12 December 2020